Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “hold” rating reiterated by equities researchers at Wedbush in a report issued on Thursday, AnalystRatings.com reports. They currently have a $1.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 16.13% from the company’s previous close.
RGLS has been the topic of a number of other research reports. Zacks Investment Research cut Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 14th. ValuEngine cut Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. Regulus Therapeutics currently has an average rating of “Hold” and a consensus price target of $1.31.
Shares of NASDAQ RGLS opened at $0.86 on Thursday. The firm’s 50-day moving average is $1.10 and its two-hundred day moving average is $0.78. The company has a market capitalization of $18.10 million, a PE ratio of -0.47 and a beta of 1.71. Regulus Therapeutics has a 12-month low of $0.50 and a 12-month high of $1.74.
Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.26). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. As a group, equities research analysts expect that Regulus Therapeutics will post -1.11 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Regulus Therapeutics stock. Renaissance Technologies LLC lifted its position in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) by 17.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 476,993 shares of the biopharmaceutical company’s stock after buying an additional 70,300 shares during the period. Renaissance Technologies LLC owned 2.27% of Regulus Therapeutics worth $425,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 36.59% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Read More: Equal Weight Rating
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.